Skip to content

A clinical study on the establishment of the whole-process management of calculus diagnosis and treatment based on big data analysis of urinary calculi

A clinical study on the establishment of the whole-process management of calculus diagnosis and treatment based on big data analysis of urinary calculi

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062657
Enrollment
Unknown
Registered
2022-08-15
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urolithiasis

Interventions

case series:NA

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who were diagnosed with calculi by medical history, signs, and preoperative imaging, and who were in line with surgical indications and underwent calculus removal; 2. The patients signed the informed consent for the operation and agreed to conduct urine microbial testing and stone composition analysis.

Exclusion criteria

Exclusion criteria: 1. The patient is diagnosed with urinary calculi but has no indication for surgery; 2. Primary or secondary hypercalcemia, including: hyperparathyroidism, milk-alkali syndrome, sarcoidosis or sarcoid-like disease, vitamin D intoxication, hyperthyroidism, pheochromocytoma, increased cortisol , adrenal insufficiency, vitamin A poisoning, etc.; 3. Patients with urinary tract stones caused by other potential causes, such as renal tubular acidosis, gout and some hereditary diseases, such as primary cystinuria, hyperuricemia, etc.; 4. Patients with congenital anatomical abnormalities, such as bladder neck stenosis, cavernous kidney, ureterocele, renal cyst, neurogenic bladder and congenital giant ureter; 5. The following medication history within two years before admission: amphotericin, HIV infection drugs (such as indinavir), magnesium silicate and sulfonamides; acetazolamide, corticosteroids, etc. 6. Patients who refuse to undergo urine microbiological analysis and stone composition analysis; 7. Patients who did not take stones according to the surgical standards during the operation; 8. Patients with malignant tumors; 9. Or at the discretion of the investigator, there may be other lesions that reduce the likelihood of inclusion or complicate inclusion.

Design outcomes

Primary

MeasureTime frame
Demographic and vital signs data: age, height, weight, ethnicity, marriage; blood pressure, heart rate;General clinical data: medical history, course of disease, treatment history, comorbid diseases, drug use and social life factors (smoking, drinking, exercise, diet), whether or not the first stone was diagnosed, whether there was repeated urinary tract infection, etc.;Perioperative data: whether antibiotics were used before surgery, whether antibiotic resistance was used before surgery, surgical method, perioperative conditions (including whether plasma transfusion, whether to upgrade antibiotics, whether to use vasopressors, maximum body temperature), blood test results;Diet Structure Survey Indicators;Psychological Questionnaire Indicators;Urine 16s rDNA microbiota test results;Stone composition analysis test results;Safety;

Countries

China

Contacts

Public ContactXiaoqiang Liu

Tianjin Medical University General Hospital

xiaoqiangliu1@163.com+86 13820915038

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026